ImageneBio (NASDAQ:IMA) Rating Lowered to Underperform at Wedbush

ImageneBio (NASDAQ:IMA - Get Free Report) was downgraded by investment analysts at Wedbush from a "neutral" rating to an "underperform" rating in a report issued on Tuesday, MarketBeat Ratings reports.A number of other equities research analysts have also recently weighed in on IMA. Weiss Ratings began coverage on shares of ImageneBio in a research note on Wednesday, October 22nd. They set a "sell (e-)" rating on the stock. Leerink Partnrs upgraded shares of ImageneBio to a "strong-buy" rating in a research report on Friday, October 24th. Wall Street Zen lowered shares of ImageneBio from a "hold" rating to a "strong sell" rating in a research note on Saturday, November 15th. Zacks Research lowered shares of ImageneBio from a "strong-buy" rating to a "hold" rating in a research note on Monday, September 29th. Finally, Leerink Partners assumed coverage on ImageneBio in a report on Friday, October 24th. They set an "outperform" rating and a $30.00 target price on the stock. One analyst has rated the stock with a Strong Buy rating, one has given a Buy rating, one has given a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat, the company has an average rating of "Hold" and an average target price of $26.50.Read Our Latest Stock Analysis on ImageneBioImageneBio Price PerformanceShares of IMA stock opened at $7.25 on Tuesday. ImageneBio has a 12-month low of $6.90 and a 12-month high of $23.28. The firm has a market capitalization of $81.07 million, a price-to-earnings ratio of -0.90 and a beta of 0.42. The business has a 50 day simple moving average of $8.01 and a 200 day simple moving average of $12.30. ImageneBio (NASDAQ:IMA - Get Free Report) last announced its earnings results on Wednesday, November 12th. The company reported ($2.91) earnings per share for the quarter, missing the consensus estimate of ($1.47) by ($1.44). On average, equities analysts anticipate that ImageneBio will post -0.91 EPS for the current fiscal year. Institutional Investors Weigh In On ImageneBioSeveral hedge funds have recently made changes to their positions in IMA. Deep Track Capital LP purchased a new stake in shares of ImageneBio in the 3rd quarter valued at approximately $7,160,000. Blue Owl Capital Holdings LP acquired a new stake in ImageneBio during the 3rd quarter valued at $4,409,000. Atlas Venture Life Science Advisors LLC purchased a new stake in shares of ImageneBio in the third quarter valued at $3,079,000. Aldebaran Capital LLC purchased a new position in shares of ImageneBio during the first quarter valued at $317,000. Finally, Vanguard Group Inc. acquired a new position in ImageneBio during the third quarter valued at $1,902,000. Hedge funds and other institutional investors own 75.00% of the company's stock. ImageneBio Company Profile (Get Free Report)ImageneBio, Inc, a clinical-stage biotechnology company, develops therapeutics for immunological and inflammatory diseases. Its lead product includes IMG-007, a non-depleting anti-OX40 mAb that has completed Phase 2a clinical trials for the treatment of atopic dermatitis and alopecia areata. The company was formerly known as Ikena Oncology, Inc and changed its name to ImageneBio, Inc in July 2025.See AlsoFive stocks we like better than ImageneBioStock Splits, Do They Really Impact Investors?History Says These are 3 Stocks to Buy for DecemberFollowing Congress Stock TradesWarner Bros. Sale Rumors Heat Up: What Investors Need to KnowStock Market Upgrades: What Are They?From Science Project to Solvent: WeRide’s 761% Revenue SurgeShould You Invest $1,000 in ImageneBio Right Now?Before you consider ImageneBio, you'll want to hear this.MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ImageneBio wasn't on the list.While ImageneBio currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.View The Five Stocks Here